Free Submission Public Relations &
Deutsch English


"EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US" Published

Print article Print article
2013-04-19 18:13:50 - Epidemiology Forecast to 2022

Respiratory syncytial virus (RSV) is one of the most common causes of respiratory infections in children. The majority of cases present with mild, cold-like symptoms, but about 1% of cases develop severe complications requiring hospitalization. Children under two years of age with certain health conditions are most at risk for severe RSV infections and are therefore recommended to receive RSV prophylaxis treatments (Resch, 2011).

GlobalData epidemiologists forecasted the RSV infection population and each prophylactic population in the US independently based on trends in population, birth, infant mortality, disease incidence, and disease survival. GlobalData epidemiologists estimate that RSV infections will grow 10.4% in the next decade, from 8.03 million cases in 2012 to 8.87 million cases in 2022. The number of RSV

infections is expected to increase due to population growth while the prophylactic populations are expected to decrease due to decreased births and decreased preterm births. Improvements in prenatal care in the US, increased pre-birth screening of congenital abnormalities, and advancement in treatments are all drivers of the decrease in preterm births.

Full Report Details at
- ..


The Respiratory Syncytial Virus Infections and Prophylactics Populations EpiCast Report provides overview of the risk factors for severe RSV infections, as well as a 10-year epidemiology forecast of primary, secondary, and hospitalized RSV infections and RSV prophylactic populations in children aged 0-2 years in the US. The prophylactic populations are -

* Children born before 36 weeks of gestation
* Infants with neonatal chronic lung disease
* Children with congenital respiratory or neuromuscular diseases that compromises respiratory function
* Children with hemodynamically significant congenital heart diseases
* The RSV infection population and RSV prophylactic populations are further segmented by age (0-year, 1-year, and 2-year) and by sex.

Reasons to buy

* Develop business strategies by understanding the trends shaping and driving the US prophylactics populations.
* Quantify infection and prophylactic populations in the US to improve product development, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the prophylactic group that present the best opportunities for prophylactic therapeutics in each of the markets covered.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Reports
3 Epidemiology
3.1 Risk Factors and Comorbidities
3.1.1 Re-hospitalization rate increases with lower gestational age
3.1.2 Congenital respiratory or neuromuscular diseases are more often re-hospitalized
3.1.3 Re-hospitalization is more frequent in chronic lung disease infants
3.1.4 More complications in children with hemodynamically significant congenital heart disease
3.1.5 Hospitalized cases likely to develop long-term respiratory problems
3.2 Trends in the US
3.2.1 RSV Infections and Hospitalization Rates
3.2.2 Preterm Births and Infant Mortality
3.2.3 Congenital Respiratory or Neuromuscular Diseases
3.2.4 Neonatal Chronic Lung Disease
3.2.5 Hemodynamically Significant Congenital Heart Diseases
3.3 Forecast Methodology
3.3.1 Sources Used
3.3.2 Forecast Assumptions and Methods (US)
3.3.3 Sources Not Used
3.4 Epidemiological Forecast of RSV Infections and Prophylactic Populations
3.4.1 Primary, Secondary, and Hospitalizations of RSV Infections
3.4.2 Preterm Population
3.4.3 Congenital Respiratory or Neuromuscular Diseases Population
3.4.4 Neonatal Chronic Lung Disease Population
3.4.5 Hemodynamically Significant Congenital Heart Diseases Population
3.4.6 RSV Infections and Prophylactic Populations Segmented by Sex
3.5 Discussion
3.5.1 Conclusions on Epidemiological Trends and Forecast
3.5.2 Limitations in Analysis
3.5.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Sources Used for Incidence or Prevalence
Table 2: Definitions of Neonatal Chronic Lung Disease
Table 3: Respiratory Syncytial Virus Infections, 0-2 Years, Boys and Girls, N (Column Select Years 2012-2022
Table 4: Preterm Population, Boys and Girls, 0-2 Years, N (Column Select Years 2012-2022
Table 5: Congenital Respiratory or Neuromuscular Diseases Population*, Boys and Girls, 0-2 Years, N (Column %), Select Years 2012-2022
Table 6: Neonatal Chronic Lung Disease Population, Boys and Girls, Age 0, N (Column %), Select Years 2012-2022
Table 7: Hemodynamically Significant Congenital Heart Diseases Population, Boys and Girls, N (Column %), 0-2 Years, Select Years 2012-2022
Table 8: RSV Infection and Prophylactic Populations by Sex, 0-2 Years, N (Row %), 2012

List of Figures

1.2 List of Figures
Figure 1: Population Estimate and Births Forecast in the US, Boys and Girls, 1997-2022
Figure 2: Respiratory Syncytial Virus Infections by Age and Infection Type, Boys and Girls, N (Millions), 2012 and 2022
Figure 3: Preterm Population, Boys and Girls, 0-2 Years, N (Millions), 2012-2022
Figure 4: Preterm Population (<36 Weeks of Gestation) Segmented by Sex, 0-2 Years, N (Thousands), 2012
Figure 5: Respiratory Syncytial Virus Infections Segmented by Sex, 0-2 Years, N (Millions), 2012

Full Table of Contents is available at:

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact